New drug combo aims for long remission in untreated CLL patients
NCT ID NCT04458610
First seen Jan 13, 2026 · Last updated Jun 08, 2026 · Updated 17 times
Summary
This study is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not yet had treatment. It tests a combination of two drugs: zanubrutinib (which blocks a protein that helps cancer cells grow) and rituximab (an antibody that helps the immune system attack cancer cells). The main goal is to see how many patients can stop treatment and stay in remission for at least 6 months. About 60 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.